Riley Bove, MD — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications2liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Bazedoxifene AcetateThe primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS). The investigators will utilize electrophysiologic techniques and magnetic resonance imaging to quantify the effect of treatment in 50 women over the course of 6 months. Participants may remain on their standard disease modifying treatment during the course of the trial but may not concurrently participate in any other investigational new drug research study.	SEP	Phase 2	Remyélinisation	United States	À vérifier
Bazedoxifene AcetateThe primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS). The investigators will utilize electrophysiologic techniques and magnetic resonance imaging to quantify the effect of treatment in 50 women over the course of 6 months. Participants may remain on their standard disease modifying treatment during the course of the trial but may not concurrently participate in any other investigational new drug research study.	SEP	Phase 2	Remyélinisation	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Bazedoxifene Acetate	SEP	Phase 2	NCT04002934	ReWRAP — Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis	COMPLETED

Publications

2

Molécule	Indication / population	Titre	Journal	Date
Bazedoxifene Acetate		Therapeutic Potential of Compounds with High Affinity to BAG2 in Inhibiting Keloid Disease.	Biologics : targets & therapy
Bazedoxifene Acetate		Identification and characterization of anti-chikungunya virus compounds using a biosafe toolkit.	Virologica Sinica